Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy

• Main Authors: Sankaranarayan Kannan (Author), Mary E. Irwin (Author), Shelley M. Herbrich (Author), Tiewei Cheng (Author), LaNisha L. Patterson (Author), Marisa J. L. Aitken (Author), Kapil Bhalla (Author), M. James You (Author), Marina Konopleva (Author), Patrick A. Zweidler-McKay (Author), Joya Chandra (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Acute myeloid leukemia (AML) is a molecularly heterogenous hematological malignancy, with one of the most common mutations being internal tandem duplication (ITD) of the juxtamembrane domain of the fms-like tyrosine kinase receptor-3 (FLT3). Despite the development of FLT3-directed tyrosine kinase i...